Xencor Inc. Stock
Price
Target price
?
?
0.000%
-
0.000%
€22.87
07:38 / Stuttgart Stock Exchange
WKN: A1W96L / Symbol: XNCR / Name: Xencor / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Xencor Inc. Stock
There is no change in the price for Xencor Inc. today.
We see a rather positive sentiment for Xencor Inc. with 15 Buy predictions and 2 Sell predictions.
As a result the target price of 22 € shows a very positive potential of 52.78% compared to the current price of 14.4 € for Xencor Inc..
Pros and Cons of Xencor Inc. in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xencor Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xencor Inc. | 0.000% | -1.370% | 23.077% | -39.496% | -36.842% | -48.571% | -57.143% |
| Ironwood Pharmaceuticals | -2.550% | 0.641% | 46.729% | -10.795% | -25.238% | -71.640% | -68.122% |
| Novocure Ltd | 4.330% | 15.035% | 13.574% | -60.802% | -60.062% | -83.741% | -91.793% |
| Iovance Biotherapeutics Inc. | 1.740% | 1.443% | -16.260% | -76.601% | -72.311% | -70.837% | -95.364% |
Comments
Xencor (NASDAQ:XNCR) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor (NASDAQ:XNCR) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $26.00 price target on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor (NASDAQ:XNCR) had its price target raised by analysts at Royal Bank Of Canada from $18.00 to $19.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
News
Xencor (XNCR) Q2 Revenue Jumps 82%
Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered antibodies for serious diseases, reported second quarter 2025 results on August 6, 2025. The company’s GAAP
